Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Bridging PK of FB825 SC in Healthy Adults
NCT05952986Phase 1Unknown
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- May 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FB825 in atopic dermatitis (AD) (3 cohorts), sponsored by Oneness Biotech Co., Ltd. Primary endpoints: Incidence of adverse event at 24 months, Area under the concentration-time curve from time zero to infinity at 19 months and 2 more. Status: unknown.
02
Drugs
FB825
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05952986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952986.